主页 > 医学动态 >

【技术产业】医疗专家与立法者:关注直接面向

September 19, 2008 (Washington, DC) — Lawmakers in Washington, DC, gathered this week to discuss recommendations for increased regulations on direct-to-consumer (DTC) advertisements for medical devices. On hand were several witnesses, including two cardiologists and an orthopedic surgeon, to discuss growing concerns about device companies, such as those who manufacture stents for PCI, advertising their products directly to the public.

"Unlike the direct-to-consumer advertising of drugs, direct-to-consumer advertising of medical devices has not yet been highly scrutinized," said Sen Herb Kohl (D-WI), chair of the Senate Aging Committee. "The medical-device industry is just beginning to get into the game. Over the past four or five years, their use of DTC ads is growing in print and on the internet."

The device industry spends just a fraction on DTC advertising compared with the pharmaceutical industry. One study cited $160 million spent on advertising to consumers in 2005 compared with the $4 billion spent by the pharmaceutical companies. The concern, however, is that spending is increasing, but more important, the products advertised require invasive surgical procedures to implant.

Consumers Unable to Assess Complex Medical Choices

The direct-to-consumer ad serves this higher goal no better than the average political ad serves the ideals of the democratic process. It simply introduces another myopic link in the chain, consumer opinion.

Speaking before the senate committee, Dr William Boden (Buffalo General Hospital, NY) asked permission to first play one of the device ads, a 60-second commercial for the Cypher stent by Johnson & Johnson that debuted on Thanksgiving weekend 2007 during an NFL football game between the Dallas Cowboys and the New York Jets. The Cypher TV ad starts with a man slumped in a chair and asks, "How big is the world? Ask the tough guy cornered by chest pains." It then shows several other people enjoying various different physical activities and says: "When your arteries narrow, so does your life," and, "It's time to open it up."

Boden has been critical of the ads in the past and, along with Dr George Diamond (Cedars Sinai Medical Center, Los Angeles, CA), who also attended the senate committee hearing, previously wrote an editorial questioning their value to the public and physicians [1]. Both told the senate committee they have concerns about the Cypher stent ad because the decision to use a stent or to use that particular stent requires sophisticated medical understanding beyond the domain of the public.

"We believe that this initial medical advertisement has crossed the line in promoting a particular coronary device to millions of individuals who are unable to discern many of the subtle and complex therapeutic issues that even we cardiac specialists continue to debate," Boden told the committee. He previously said that the idea of consumers requesting not only a stent but a specific brand and model of stent is frightening, if not utterly absurd.

"The goal of medicine . . . is to improve longevity or quality of life," Diamond told the committee. "The direct-to-consumer ad serves this higher goal no better than the average political ad serves the ideals of the democratic process. It simply introduces another myopic link in the chain, consumer opinion."

Boden offered some suggestions to the committee, the first being that the Food and Drug Administration place drug and device advertising on the same regulatory footing, and then that all DTC advertisements highlight only evidence-based clinical data that reflect the proven benefit. Boden said there is a need for a multidisciplinary committee to vet and discuss all advertising before it heads to the air, and there should be a ban on DTC advertising of drugs/devices for two years after FDA approval to make sure the drug/device fulfills postmarketing safety surveillance.

Orthopedic surgeon Dr Kevin Bozick (University of California, San Francisco), speaking on behalf of the American Association of Hip and Knee Surgeons and American Association of Orthopedic Surgeons, noted that proponents of DTC advertising say the commercials empower patients, encourage dialogue with physicians about treatment options, and eliminate the stigma of certain conditions.

"Conversely, opponents claim that DTC advertising does not educate consumers, because the information contained in DTC ads is biased and misleading and benefits of the drug or device are exaggerated and risks are at best downplayed," said Bozick. "Additionally, opponents argue that DTC advertising significantly strains the doctor-patient relationship by increasing the length of office visits and diminishing the role of the physician in clinical decision making."

Bozick cited his study that found 74% of surgeons thought the ads "negatively impacted their relationships with patients" and 84% thought patients had "unrealistic expectations regarding the benefits" of the devices after seeing the ads.

Role of the FDA

阅读本文的人还阅读:

【社会人文】如果不给予

【bio-news】直接观察细胞

作者:admin@医学,生命科学    2011-05-24 05:11
医学,生命科学网